A phase 3 trial of Intellia Therapeutics’ in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...
Incyte’s povorcitinib has scored a pair of phase 3 wins for a skin condition, although analysts noted the oral JAK inhibitor ...
Phase 2 data from PTC Therapeutics showed that the Novartis-partnered Huntington’s disease asset slowed progression by more ...
Soligenix halts its late-stage CTCL trial for futility, forcing a reassessment of its lead drug and future direction.
The high-priority National Security Space Launch Phase 3 missions include six launches in FY2027, nine in FY2028 and 10 in ...
Topline Phase 3 results of survodutide—licensed to Boehringer Ingelheim from Zealand Pharma—are more comparable to Novo ...
Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve ...
Nipocalimab demonstrates significant long-term efficacy and safety in generalized myasthenia gravis, improving MG-ADL scores and reducing immunoglobulin G levels. The phase 3 Vivacity-MG3 study ...
Phase 3 trials for chronic weight management planned for initiation in the second half of 2026 Petrelintide demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results